The effect of nizatidine on duodenal ulcer healing and on mucosal inflammatory mediators.
The aim of this double-blind, randomized, placebo-controlled trial was to evaluate the effect of nizatidine on duodenal ulcer healing and generation of mucosal prostaglandin estradiol and inflammatory mediators. Fifty-five patients with endoscopically proven active duodenal ulcer received either nizatidine 300 mg or placebo, once nightly, for 4 weeks, when a second endoscopy was performed. Healing was defined as complete epithelialization of the ulcer crater. At both endoscopies mucosal biopsies were obtained for determination of prostanoids and inflammatory mediators. Nizatidine and placebo induced ulcer healing in 76% and 60.9% of the patients, respectively, but the difference did not reach statistical significance. Nizatidine treatment did not significantly affect mucosal leukotriene B4, leukotriene C4 or platelet activating factor generation. It is concluded, therefore, that the antisecretory effect is probably the main mechanism responsible for nizatidine's therapeutic effects in peptic ulcer disease.
Eliakim
R
R
Department of Medicine, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel.
Stalnikowicz
R
R
Ackerman
Z
Z
Karmeli
F
F
Rachmilewitz
D
D
D000328:Adult; D000368:Aged; D015232:Dinoprostone / Q000378:metabolism; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism; D005773:Gastroscopy; D006801:Humans; D007975:Leukotriene B4 / Q000378:metabolism; D017997:Leukotriene C4 / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D016567:Nizatidine / Q000627:therapeutic use*; D010972:Platelet Activating Factor / Q000378:metabolism; D011863:Radioimmunoassay; D012307:Risk Factors
D010972:Platelet Activating Factor; D007975:Leukotriene B4; D017997:Leukotriene C4; D015232:Dinoprostone; D016567:Nizatidine